The genomic landscape of response to EGFR blockade in colorectal cancer

Andrea Bertotti, Eniko Papp, Siân Jones, +32

Nature

OncologyGenomic LandscapeMedicinePathologyColorectal Cancer +7

Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy

Mikkel W. Pedersen, Helle J. Jacobsen, Klaus Koefoed, +4

Cancer Research

Anti-egfr Monoclonal AntibodiesEgfr InternalizationImmunologySuperior Anticancer EfficacyImmune Checkpoint Inhibitor +10

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

Clara Montagut, Guillem Argilés, Fortunato Ciardiello, +29

JAMA Oncology

CD4⁺ and CD8a⁺ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models

Lotte K. Kristensen, Camilla Fröhlich, Camilla L. Christensen, +7

Theranostics

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

Klaus Koefoed, Lucilla Steinaa, Josefine Nielsen Søderberg, +8

mAbs

Immunocytochemical TechniqueHuman GrowthImmunologyPathologyRational Identification +19

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity

Helle J. Jacobsen, Thomas T. Poulsen, Anna Dahlman, +10

Clinical Cancer Research

Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab

Mari Iida, Toni M. Brand, Megan M. Starr, +7

Neoplasia

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype

Barbara Lupo, Francesco Sassi, Marika Pinnelli, +29

Science Translational Medicine

Tumor BiologyGastrointestinal OncologyPi3k SignalingMedicineMaximal Response +12

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

Rodrigo Dienstmann, Amita Patnaik, Rocio García‐Carbonero, +16

Cancer Discovery

Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors

Henrik Søndergaard, Klaus Stensgaard Frederiksen, Peter Thygesen, +5

Cancer Immunology Immunotherapy

T-regulatory CellImmunologyInterleukin 21Immune Checkpoint InhibitorAutoimmunity +7